BioSource Announces Stock Repurchase Program.

CAMARILLO, Calif. -- BioSource International, Inc. (Nasdaq:BIOI) today announced that the Company's Board of Directors has approved the expenditure of up to $10 million to repurchase the Company's common stock. At the discretion of the Company, purchases may be made from time to time in the open market at prevailing market prices and may also be made in privately negotiated transactions.

The number of shares of common stock actually acquired by the Company and the timing of such acquisitions will depend on subsequent developments and corporate needs, and the repurchase of shares may be interrupted or discontinued at any time.

Terrance J. Bieker, President and CEO, stated, "Given the strength of our balance sheet, our Board of Directors approved the stock repurchase program due to the disparity between the perceived value of the Company and the prices at which the stock has recently traded. We remain confident in our business strategies and BioSource's long-term growth prospects."

About BioSource International, Inc.

BioSource International, Inc. is a broad-based life sciences company focused on providing integrated solutions in the areas of functional genomics, proteomics, and drug discovery through the development, manufacturing, marketing, and distribution of unique, biologically active reagent systems which facilitate, enable, and accelerate pharmaceutical development and biomedical research. For more information, please visit the Company's Web site at www.biosource.com.

Statements included in this release that are not historical facts may be considered forward-looking statements that are subject to a variety of risks and uncertainties. For these statements, we claim the safe harbor for "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Factors that could cause actual results to differ and vary materially from expectations include, but are not limited to, our ability to expand our product offerings and any transition to new products, product quality and availability, any change in business conditions, changes in our sales strategy and product development plans, competitive pricing pressures, continued market acceptance of our products, name recognition of our products, delays in the development of new technology, intellectual property and proprietary rights may not be valid or infringe the rights of others, changes in customer buying pattern issues, one-time events, and other important factors disclosed previously and from time to time in our filings with the Securities and Exchange Commission. These cautionary statements by us should not be construed as exhaustive or as any admission regarding the adequacy of disclosures made by us. We cannot always predict or determine after the fact what factors would cause actual results to differ materially from those indicated by the forward-looking statements or other statements. In addition, readers are urged to consider statements that include the terms "believes," "belief," "expects," "plans," "objectives," "anticipates," "intends," "targets," "projections," or the like to be uncertain and forward looking. All cautionary statements should be read as being applicable to all forward-looking statements wherever they appear. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.